JP2019501133A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501133A5
JP2019501133A5 JP2018526682A JP2018526682A JP2019501133A5 JP 2019501133 A5 JP2019501133 A5 JP 2019501133A5 JP 2018526682 A JP2018526682 A JP 2018526682A JP 2018526682 A JP2018526682 A JP 2018526682A JP 2019501133 A5 JP2019501133 A5 JP 2019501133A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018526682A
Other languages
English (en)
Japanese (ja)
Other versions
JP6778747B2 (ja
JP2019501133A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063254 external-priority patent/WO2017091544A1/en
Publication of JP2019501133A publication Critical patent/JP2019501133A/ja
Publication of JP2019501133A5 publication Critical patent/JP2019501133A5/ja
Application granted granted Critical
Publication of JP6778747B2 publication Critical patent/JP6778747B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018526682A 2015-11-24 2016-11-22 胃腸炎症性腸疾患の処置のための、jak阻害剤化合物のプロドラッグ Active JP6778747B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259273P 2015-11-24 2015-11-24
US62/259,273 2015-11-24
PCT/US2016/063254 WO2017091544A1 (en) 2015-11-24 2016-11-22 Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020141651A Division JP2020196742A (ja) 2015-11-24 2020-08-25 胃腸炎症性腸疾患の処置のための、jak阻害剤化合物のプロドラッグ

Publications (3)

Publication Number Publication Date
JP2019501133A JP2019501133A (ja) 2019-01-17
JP2019501133A5 true JP2019501133A5 (https=) 2019-11-14
JP6778747B2 JP6778747B2 (ja) 2020-11-04

Family

ID=57518004

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018526682A Active JP6778747B2 (ja) 2015-11-24 2016-11-22 胃腸炎症性腸疾患の処置のための、jak阻害剤化合物のプロドラッグ
JP2020141651A Pending JP2020196742A (ja) 2015-11-24 2020-08-25 胃腸炎症性腸疾患の処置のための、jak阻害剤化合物のプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020141651A Pending JP2020196742A (ja) 2015-11-24 2020-08-25 胃腸炎症性腸疾患の処置のための、jak阻害剤化合物のプロドラッグ

Country Status (33)

Country Link
US (3) US10435428B2 (https=)
EP (1) EP3380486B1 (https=)
JP (2) JP6778747B2 (https=)
KR (1) KR20180080330A (https=)
CN (1) CN108290918B (https=)
AU (1) AU2016359494B2 (https=)
BR (1) BR112018010650A8 (https=)
CA (1) CA3003283A1 (https=)
CL (1) CL2018001345A1 (https=)
CO (1) CO2018005327A2 (https=)
CY (1) CY1122918T1 (https=)
DK (1) DK3380486T3 (https=)
EA (1) EA035816B1 (https=)
ES (1) ES2784523T3 (https=)
HR (1) HRP20200561T1 (https=)
HU (1) HUE049775T2 (https=)
IL (1) IL259076B (https=)
LT (1) LT3380486T (https=)
ME (1) ME03757B (https=)
MX (1) MX383107B (https=)
MY (1) MY189979A (https=)
NZ (1) NZ742574A (https=)
PH (1) PH12018501037A1 (https=)
PL (1) PL3380486T3 (https=)
PT (1) PT3380486T (https=)
RS (1) RS60237B1 (https=)
SG (1) SG11201803686UA (https=)
SI (1) SI3380486T1 (https=)
SM (1) SMT202000242T1 (https=)
TW (1) TWI703147B (https=)
UA (1) UA121270C2 (https=)
WO (1) WO2017091544A1 (https=)
ZA (1) ZA201802967B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US10556901B2 (en) 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
ES2784523T3 (es) 2015-11-24 2020-09-28 Theravance Biopharma R&D Ip Llc Profármacos de un compuesto inhibidor de JAK para el tratamiento de enfermedades inflamatorias gastrointestinales
FR3060567B1 (fr) * 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
US10472366B2 (en) 2017-03-08 2019-11-12 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
BR112019024509A2 (pt) 2017-05-23 2020-06-23 Theravance Biopharma R&D Ip, Llc Glicuronídeo de pró-fármacos dos inibidores da janus quinase
WO2018217699A1 (en) * 2017-05-23 2018-11-29 Theravance Biopharma R&D Ip, Llc Thiocarbamate prodrugs of tofacitinib
EP3634430B1 (en) * 2017-06-05 2024-08-07 Flagship Pioneering Innovations V, Inc. Multibiotic agents and methods of using the same
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
WO2019182322A1 (ko) * 2018-03-20 2019-09-26 삼진제약주식회사 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
CN112955431A (zh) * 2018-09-06 2021-06-11 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
CN109134564B (zh) * 2018-09-21 2022-03-11 合肥锐思生物医药有限公司 乳果糖糖苷衍生物、其制备方法及其用途
EA202191354A1 (ru) * 2018-11-15 2021-08-11 Янссен Байотек, Инк. Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника
CA3123596A1 (en) * 2018-12-19 2020-06-25 Incyte Corporation Jak1 pathway inhibitors for the treatment of gastrointestinal disease
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021097074A1 (en) * 2019-11-13 2021-05-20 New York University Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230107927A1 (en) * 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
TW202207918A (zh) 2020-05-14 2022-03-01 美商施萬生物製藥研發Ip有限責任公司 腸道選擇性jak3抑制劑的投與
CN113943312A (zh) * 2020-07-17 2022-01-18 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
WO2022087313A1 (en) * 2020-10-22 2022-04-28 Progenity, Inc. Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases
EP4351584A4 (en) * 2021-06-07 2025-04-23 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING CELIAC DISEASE
CN117355527B (zh) * 2021-07-20 2024-06-07 上海椿安生物医药科技有限公司 一种消炎偶联化合物药物及其制法和应用
EP4525835A2 (en) * 2022-05-14 2025-03-26 3-D Matrix Ltd. Novel formulations for oral administration of therapeutic agents to the gastrointestinal tract
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用
CN117567460A (zh) * 2022-08-08 2024-02-20 明慧医药(杭州)有限公司 一种前药化合物及其制备方法和用途
EP4573084A1 (en) 2022-08-17 2025-06-25 Transcend Therapeutics, Inc. Phenethylamines and cathinones precursors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022334A1 (en) 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
KR101921850B1 (ko) 2009-10-09 2018-11-23 인사이트 홀딩스 코포레이션 3-(4-(7H-피롤로〔2,3-d〕피리미딘-4-일)-1H-피라졸-1-일)-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
EP2695617B1 (en) 2009-12-23 2019-01-09 Glycomyr Inc. Vitamin D glycosides and sulfates for treating intestinal diseases
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
JP2013518882A (ja) * 2010-02-05 2013-05-23 ファイザー・インク JAK阻害剤としてのピロロ[2,3−d]ピリミジン尿素化合物
US20130109720A1 (en) 2011-11-01 2013-05-02 Hoffmann-La Roche Inc. Indole inhibitors of crac
JP2016528174A (ja) * 2013-05-31 2016-09-15 セルリアン・ファーマ・インコーポレイテッド 治療的送達用のシクロデキストリンベースのポリマー
EP3169348B1 (en) * 2014-06-24 2019-07-31 Institut National de la Sante et de la Recherche Medicale (INSERM) Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases
ES2784523T3 (es) 2015-11-24 2020-09-28 Theravance Biopharma R&D Ip Llc Profármacos de un compuesto inhibidor de JAK para el tratamiento de enfermedades inflamatorias gastrointestinales
ES2954596T3 (es) 2015-12-23 2023-11-23 Univ British Columbia Profármacos unidos a lípidos
CN106496233B (zh) 2016-09-26 2018-05-15 东南大学 吡咯并嘧啶类化合物、其制备方法及其用途

Similar Documents

Publication Publication Date Title
JP2019501133A5 (https=)
KR102488479B1 (ko) 인플루엔자 바이러스 감염에 사용하기 위한 인돌
JP6716785B2 (ja) Hivウイルス感染症の予防的または治療的処置に有用な治療用化合物
CN107207498B (zh) 用于治疗hiv的稠合嘧啶化合物
TWI649308B (zh) 喹啉衍生物
JP2014511892A5 (https=)
CN118766947A (zh) 用于治疗SARS CoV-2感染的方法
JP2016534063A5 (https=)
AU2014348840B2 (en) Inhibitors of influenza viruses replication
HRP20200561T1 (hr) Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti
JP2012524056A5 (https=)
JP2015511638A5 (https=)
JP2017518334A5 (https=)
KR20180021730A (ko) 티로신 키나제 억제제
JP2019500387A5 (https=)
JP2013518107A5 (https=)
JP2013542261A5 (https=)
JP2014511891A5 (https=)
JP2013544846A5 (https=)
JP2011529071A5 (https=)
JP2016506962A5 (https=)
JP2017526677A5 (https=)
JP2014513110A5 (https=)
JP2017531619A5 (https=)
US20220001015A1 (en) Lymphatic system-directing lipid prodrugs